Aerie Pharmaceuticals Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/28/2022)
| Balance Sheet | Total Assets | 431,391,000.00 | ROE | – |
| Balance Sheet | Total Equity | -17,333,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -3,291,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -102,445,000.00 | – | – |
| Cashflow | Operating Cash Flow | -99,154,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -1.61 | Div. Yield | – |
| Income | Net Income | -74,810,000.00 | P/E | – |
| Income | Shares Outstanding | 46,342,900.00 | P/B | – |
| Income | Total Revenue | 194,134,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.aeriepharma.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more